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Abstract
Background: Nosocomial infections are extremely common in the elderly and may be related to ageing of the
immune system. The Immune Risk Phenotype (IRP), which predicts shorter survival in elderly patients, has not been
evaluated as a possible risk factor for nosocomial infection. Our aim was to assess the prevalence of nosocomial
infections in elderly in-patients and to investigate potential relationships between nosocomial infections and the
immunophenotype, including IRP parameters.
Results: We included 252 consecutive in-patients aged 70 years or over (mean age, 85 ± 6.2 years), between 2006
and 2008. Among them, 97 experienced nosocomial infections, yielding a prevalence rate of 38.5% (95%
confidence interval, 32.5-44.5). The main infection sites were the respiratory tract (21%) and urinary tract (17.1%)
When we compared immunological parameters including cell counts determined by flow cytometry in the groups
with and without nosocomial infections, we found that the group with nosocomial infections had significantly
lower values for the CD4/CD8 ratio and naive CD8 and CD4 T-cell counts and higher counts of memory CD8 T-
cells with a significant increase in CD28-negative CD8-T cells. Neither cytomegalovirus status (positive in 193/246
patients) nor presence of the IRP was associated with nosocomial infections. However, nosocomial pneumonia was
significantly more common among IRP-positive patients than IRP-negative patients (17/60 versus 28/180; p =
0.036).
Conclusion: Immunological parameters that are easy to determine in everyday practice and known to be
associated with immune system ageing and shorter survival in the elderly are also associated with an elevated risk
of nosocomial pneumonia in the relatively short term.
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Background
Nosocomial infections (NIs) constitute a major public
health concern, as they are common and associated with
both high morbidity and mortality rates and high
healthcare costs [1,2]. Risk factors for NIs vary with the
infection site, healthcare setting, and patient age. The
National Nosocomial Infections Survey done in the US
in 1986-1990 showed that 54% of all NIs occurred in
people aged 65 or over [3]. In elderly individuals, the
increased susceptibility to severe infections and
decreased efficacy of vaccination may reflect ageing of
the immune system, or immunosenescence, which
involves nearly all the components of the immune sys-
tem [4-6].
Among the changes characteristic of immunosenes-
cence, those believed to play a major role include the
progressive decline in naive circulating T-cell counts
(paralleling involution of the thymus), expansion of
memory T-cells, and accumulation of terminally differ-
entiated effector CD8 T-cells characterised by loss of
CD28 expression [7]. Peripheral CD28- CD8 T-cell
counts are elevated in elderly individuals [8-10]. The
expansion of this T-cell subset is related to the clonal
T-cell expansions often detected in elderly individuals
and leads to competition for CD8 T-cell survival niches,
thereby hampering the immune responses to infections,
most notably those of viral origin [10].
Cytomegalovirus (CMV) is considered crucial among
the repeated antigenic stimuli responsible for the
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accumulation of oligoclonal effector CD8 T cells [11,12].
Actively keeping CMV in its latent state via the anti-
viral immune response places an enormous burden on
the entire adaptive immune system [13] and makes a
substantial contribution to the phenotype changes
observed in T-cell subsets in elderly people [14].
Geriatric studies have identified several alterations in
immunological parameters that are associated with
shorter survival in elderly individuals. The term
“immune risk phenotype” (IRP) was defined by Pawelec
et al. [15] as the combination of high CD8 and low CD4
T-cell counts with a poor proliferative response to con-
canavalin A and low percentages of B-cells. The IRP
predicted a 2- to 4-year decrease in survival among free-
living healthy Swedes over 85 years of age (OCTO
study, [16]). Subsequently, the definition of the IRP was
simplified to inversion of the CD4/CD8 T-cell ratio [17].
Serological evidence of persistent CMV infection was
then found to be strongly associated with CD28- CD8
T-cell expansion and was consequently added to the
definition of the IRP [18]. In the NONA longitudinal
study of IRP parameters in a cohort of elderly out-
patients not selected for good health, the IRP was asso-
ciated with a higher mortality rate [19]. To the best of
our knowledge, immunosenescence as a possible risk
factor for NIs in elderly patients has not been evaluated
previously.
The aims of this study were to prospectively assess the
prevalence of NIs in elderly in-patients and to look for
potential relationships between the occurrence of NIs
and the immunophenotype (i.e., main lymphocyte sub-
sets and naive and memory/effector T-cells), with spe-
cial attention to the IRP as defined in the NONA study
[19].
Results
We included 252 patients aged 70 years or over (181
[71.8%] females; mean age, 85.2 [± 6.2]) years). These
patients were transferred from acute medical units (n =
224) or orthopaedic surgical units (n = 28) to the geria-
tric rehabilitation unit of our internal medicine depart-
ment. Table 1 reports the main clinical characteristics at
admission. The most common diagnoses were cardio-
pulmonary disease (25.8%), dementia (24.2%), and osteo-
porosis or fracture (20.2%).
At least one NI was diagnosed in 97 patients, yielding
a prevalence rate of 38.5% (95%CI, 32.5-44.5%); 18
patients each had two NIs; thus the total number of NIs
was 115. The most common sites of NI were the
respiratory tract (21%) and urinary tract (17.1%).
Table 2 compares the groups with and without NIs
(NI+ and NI-, respectively). Age and sex did not differ
significantly between the groups. The CD4/CD8 ratio
was significantly lower in the NI+ group than in the NI-
group (p = 0.027). Accordingly, although CD4 T-cell
counts did not differ significantly between the groups,
the absolute CD8 T-cell count tended to be higher in
the NI+ group. Naive CD4 T-cells were significantly
decreased in the NI+ group when expressed as a percen-
tage, but the difference was no longer significant when
the counts were expressed as absolute values. The NI+
group had significantly lower naive CD8 T-cell counts
expressed as both the absolute value and the percentage,
compared to the NI- group. Counts of peripheral mem-
ory CD8 T-cells and CD28-CD8 T-cells were signifi-
cantly higher in the NI+ group, both as absolute values
and as percentages. However, in both groups, the med-
ian values of all parameters were within the normal age-
specific range.
CMV serological status was determined in 246
patients and IRP status in 240 of these 246 patients.
CMV serology was positive in 193 (78.5%) patients. In
these CMV+ patients, we found immunological changes
Table 1 Clinical characteristics of the study population at
admission to the geriatric rehabilitation department
Patients
(n = 252)
Age, mean ± SD, years 85.2 ± 6.2
Sex (male/female) 71/181
Marital status, n (%)
- married 78 (31)
- single 14 (5)
- divorced 4 (2)
- widowed 156 (62)
Living arrangements, n (%)
-home 243 (96)
-nursing home 9 (4)
Main reason for hospital admission, n (%)
- cardiopulmonary disease 65 (25.8)
- dementia 61 (24.2)
- psychiatric disease 14 (5.5)
- stroke 26 (10.3)
- neurological disease 17 (6.7)
- metabolic and other diseases 18 (7.1)
- osteoporosis and/or fracture 51 (20.2)
Patients with at least one nosocomial infection, n (%) 97 (38.5)
Sites (n = 115)
- Respiratory tract, n (%) 53 (21)
- pneumonia 45 (17.9)
- bronchitis 9 (3.6)
- Urinary tract, n (%) 43 (17.1)
- Gastrointestinal tract 3 (1.2)
- Skin 11 (4.4)
- Other 5 (2.0)
We recorded 115 infections in 97 patients; 18 patients each had two
infections at different sites.
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Table 2 Immunological characteristics of elderly patients according to occurrence of at least one nosocomial infection within 3 months after admission
Total (252 patients) Nosocomial infection (97 patients) No nosocomial infection (155 patients) p value
Age in years, mean (SD) 85 ± 6 85 ± 5.4 84 ± 6.2 0.295
Female gender, n (%) 181(67.9) 68 (70.1) 113(72.9) 0.631
CD4 T-cell count* 682 (555-967) 685 (534-951) 680 (561-990) 0.83
CD8 T-cell count* 312 (206-447) 348(207-557) 272 (206-412) 0.06
CD4/CD8 ratio 2.5 (1.4-3.5) 2.1 (1.3-3.2) 2.6 (1. 6-3.8) 0.027
NK cell count* 176 (112-258) 186 (112-262) 160 (110-255) 0.38
B cell count* 126 (78-175) 133 (78-175) 117 (78-184) 0.83
CD4 T cells
Naive (CD45RA+CD62L+)%** 17.7 (13.2-22.9) 16.3 (8.8-24.2) 18.7 (12.5-28.1) 0.03
Absolute value/μL 242 (148-388) 214 (125-385) 260 (155-390) 0.09
Memory
Peripheral (CD45RA-CD62L-)%** 6.5 (4.5-9.3) 6.6 (4.5-9.5) 6.5 (4.5-9.3) 0.49
Absolute value/μL 99 (56-152) 109 (64-156) 96 (53-150) 0.29
Central (CD45RA-CD62L+)%** 18.2 (10.5-26.9 16.9 (12.9-23.1) 18.3 (13.5-22.9) 0.35
Absolute value/μL 256 (175-351) 249 (174-358) 262 (172-350) 0.91
CD45RA+CD62L-%** 0.6 (0.3-1.4) 0.6 (0.2-1.4) 0.6 (0.3-1.3) 0.97
Absolute value/μL 9 (3-22) 9 (3-24) 9 (4-20) 0.93
CD8 T cells
Naive (CD45RA+CD62L+)% 5 (3.3-7.4) 4.3 (2.9-6.9) 5.2 (3.8-8) 0.006
Absolute value/μL 73 (44-115) 67 (39-107) 80 (46-125) 0.03
Memory
Peripheral (CD45RA-CD62L-)% 2.8 (1.5-4.9) 3.1 (1.6-6.2) 2.6 (1.4-4.0) 0.02
Absolute value/μL 44 (20-76) 49 (23-92) 37 (17-71) 0.01
Central (CD45RA-CD62L+)% 2.7 (1.7-3.9) 3 (1.8-3.9) 2.6 (1.6-4.1) 0.32
Absolute value/μL 38 (23-59) 41 (26-61) 36 (23-57) 0.22
Terminal Effector
CD45RA+CD62L-% 7.9 (4-12.9) 8.5(3.8-16.2) 7.2 (4.1-11.9) 0.15
Absolute value/μL 109 (54-191) 135(60-233) 101(54-169) 0.11
CD28-% 56.7 (42.5-73) 51.8 (40-66) 53.6 (40-68) 0.02
Absolute value/μL 153 (88-272) 196 (91-357) 139 (88-248) 0.01
IRP criteria***(n = 240)
CD4/CD8 < 1 (n = 245) 20 (8.2) 10 (10.5) 10 (6.7) 0.34
CD8 T-cells > 600 (n = 245) 32 (13.1) 17 (17.9) 15 (10.0) 0.07
CD28-CD8+ T-cells > 300 (n = 238) 64 (26.9) 31 (33.3) 33 (22.8) 0.07
Positive CMV serology (n = 246) 193 (78.5) 76 (79) 117 (78) 0.87
Positive IRP (n = 240, 95/145) 60 (25) 29 (30.5) 31 (21.4) 0.11
The data are medians and 25-75 percentiles, unless otherwise stated.
*Number of cells per microliter: the main lymphocyte subsets and terminal effector CD28- CD8 cells were counted directly as absolute numbers per microliter of blood (single-platform flow cytometry).
**% of total lymphocytes. Naive and memory subsets were assessed as percentages of total blood lymphocytes, and their absolute counts were computed based on the absolute counts of CD4 and CD8 T cells





















known to be associated with positive CMV serology
(increased peripheral memory and effector CD4 and
CD8 T-cells, data not shown). However, CMV status
was not significantly associated with NI occurrence (p =
0.87). The rate of IRP+ patients was slightly higher in
the NI+ group than in the NI- group, but the difference
was not statistically significant (p = 0.11). The rate of
nosocomial pneumonia was significantly higher in the
IRP+ group (n = 60) than in the IRP- group (17/60,
28.3% versus 28/180, 15.6%; p = 0.036). Table 3 com-
pares the IRP criteria in the 97 NI+ patients according
to the initial site of infection. No significant differences
were found across sites for a CD4/CD8 ratio < 1,
CD8T-cells > 600/μL, CD28-negative T-cells > 300
cells/μL, or positive CMV serology. In-hospital mortality
was 6% (n = 15/252) and did not differ between the IRP
+ and IRP- groups (3/60, 5% versus 12/180, 6.6%,
respectively; p = 0.76). However, in-hospital mortality
was significantly higher in patients with nosocomial
pneumonia than in the other patients (8/45,17.8% versus
7/207, 3.4%; p = 0.001).
Discussion
In our elderly population, the immunological parameters
associated with ageing of the immune system were more
severely altered at admission in the patients who subse-
quently experienced one or more NIs than in those who
remained free of NIs. More specifically, at baseline,
patients with subsequent NIs had lower CD4/CD8
ratios, higher CD8 T cell counts, lower naive CD4 and
CD8 T-cell counts, higher proportions of memory C8
T-cells, and higher counts of CD28-CD8 T-cells, com-
pared to patients without NIs. CMV status was not
associated with NIs. Moreover, patients exhibiting the
IRP had a higher rate of nosocomial pneumonia than
did the other patients.
To evaluate the immune system in our elderly
patients, we looked at two sets of abnormalities asso-
ciated with ageing: (i) classical immunology variables,
which showed decreases in naive T-cell subsets and
increases in memory/effector cells; (ii) and the IRP, a
combination of immunological alterations specifically
identified as associated with shorter survival in free-liv-
ing healthy Swedes over 85 years of age [15-17]. In sub-
sequent studies, such as the NONA study [19], the IRP
was used in cohorts of individuals not selected for good
health and was found to be unrelated to morbidity [20].
Both sets of abnormalities were present in our patients
with NIs.
A limitation of our study is that only peripheral lym-
phocytes were counted. We did not evaluate other
immune cells such as antigen-presenting cells or phago-
cytes, and we did not assess local factors at sites of
infection.
In this study, we endeavoured to determine whether
the risk of NI was predicted by immunological para-
meters. To our knowledge, the ability of immunological
abnormalities reflecting immunosenescence to predict
infections had not been studied previously in elderly in-
patients. Wikby et al. first established that the IRP was a
valuable predictor of mortality in very elderly people, a
finding later confirmed in the NONA study [17,19].
However, the NONA study did not specify the causes of
death and assessed the ability of the IRP to predict rela-
tively long-term survival (6 years in patients aged 90
years or over). Interestingly, immunosenescence as
assessed based on alterations in blood T-cell subsets has
been described in Alzheimer’s disease [21], and CMV
infection is believed to contribute to the increased sus-
ceptibility of elderly individuals to many types of
chronic antigenic stress such as cancer and autoimmu-
nity [22].
Our data indicate a greater degree of immunosenes-
cence in patients with NIs, compared to patients with-
out NIs, despite the similar mean ages in the two
groups. Moreover, patients with a positive CMV status
and at least one immunological criterion for IRP were at
increased risk for bacterial or viral pneumonia but not
for bacterial infections of the urinary tract or other sites.
This finding is consistent with the hypothesis that senes-
cent CD8 T cells cannot respond properly to viral infec-
tions [10]
Conclusion
The immunological alterations that characterise immu-
nosenescence are more pronounced in elderly in-
patients who subsequently experience NIs. The IRP pro-
file is associated with nosocomial pneumonia in the
relatively short term. The IRP parameters, which can be
assessed easily on a routine basis and are known to pre-
dict higher mortality in elderly, have been shown by our
study to also indicate a higher risk of NI, which is a
clear manifestation of dysimmunity.
Table 3 Immunological characteristics of the 97 elderly











IRP+ 17(37.8%) 7(22.5%) 5(26.3%) 0.36
CD4/CD8 < 1 6(13.9%) 4(12.1%) 0 (0%) 0.26
CD8 T-cells > 600 9(20.9%) 4(12.1%) 4(21.5%) 0.60
CD28-CD8+ T-cells
> 300
17(37.7%) 9(30%) 5(27.7%) 0.73
Positive CMV serology 39
(86.6%)
22 (68.7%) 15 (78.9%) 0.16
Patients with infection at several sites were classified based on the site
involved initially.
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Methods
Patients and study design
We established a prospective cohort between July 2006
and November 2008 in a teaching hospital (approxi-
mately 1300 beds) in the Paris conurbation, France.
Consecutive patients aged 70 years or over who were
referred to the geriatric rehabilitation unit by acute
medical or surgical units during the study period were
eligible. Patients were included if they were medically
stable at admission, required long-term care and rehabi-
litation, and had no terminal diseases (e.g., uncontrolled
malignancy or severe dementia), fever, infection, cancer,
or known dysimmunity. Patients were not included if
they spent less than 72 hours in the rehabilitation unit.
Study patients were followed up until discharge from
the geriatric unit. The study complied with the Declara-
tion of Helsinki and was approved by the Ile-de-France
IX ethics committee (Paris, France). Written informed
consent was obtained from each patient before study
inclusion.
Data collection
At study inclusion, a standardised questionnaire was
used to collect age, gender, living conditions, and main
reason for hospital admission. A blood sample was col-
lected on the same day for counts of the main periph-
eral lymphocyte subsets (T, B, NK, naive T-cells, and
memory/effector T cells) by flow cytometry and for
CMV serology. Patients were monitored closely for NIs
for 3 months or until discharge from the geriatric unit
or death.
Assessment of nosocomial infection
NIs were diagnosed by consensus between two investi-
gators (CB and FT) who were unaware of the immuno-
phenotype data. Once a week, these two investigators
visited each hospitalised patient and reviewed the medi-
cal records with the attending physician and nurse. NI
was defined as a well-documented infection that was
neither present nor incubating at admission and that
met the Centers for Disease Control definition of noso-
comial infection [23]. NIs were diagnosed based on a
combination of clinical findings (fever, pulmonary rales
or dullness, dyspnoea, cough, purulent sputum, dysuria,
urgency, suprapubic tenderness, clinical evidence of sep-
sis, and/or purulent drainage from a surgical incision),
laboratory test results (blood and urine cultures, isola-
tion of a pathogen from other specimens, and antigen-
or antibody-detection tests), and findings from imaging
studies (e.g., radiographs and computed tomography).
We considered only active NIs, defined as under treat-
ment with antimicrobial agents or considered on-going
by the healthcare staff. When patients experienced more
than one NI, only the first episode was considered in
the statistical analysis. The study design did not involve
specific tests for viral infections. We considered that
nosocomial respiratory tract infections were either bac-
terial or viral and that infections at other sites were
bacterial.
Flow cytometry lymphocyte counts
At study inclusion, each patient had 4 ml of peripheral
blood drawn and handled according to established clini-
cal guidelines. Absolute counts of peripheral blood CD4
and CD8 T-cells, B cells, and NK cells were obtained
directly using a Cyto-Stat tetraCHROME™ device
(Beckman-Coulter, Hyaley, Florida). CD4 T cells were
defined as CD3+CD4+ lymphocytes, CD8 T cells as
CD3+CD8+ lymphocytes, NK cells as CD3- CD16+ and/
or CD56+ lymphocytes, and B-cells as CD19+ lympho-
cytes. Reference values had been determined previously
in our laboratory.
Naive, memory, and effector T cell counts can be
determined based on the expression of CD45RA and
CD62L [24]. Two additional combinations of monoclo-
nal antibodies (from Beckman-Coulter, unless otherwise
stated) were used to determine the relative percentages
of CD8 and CD4 naive T cells (CD45RA+CD62L+),
memory T cells (central, i.e., recirculating in secondary
lymphoid organs, CD45RA-CD62L+; or peripheral, i.e.,
recirculating in effector sites, CD45RA-CD62L-), and
terminal effector T-cells (CD45RA+CD62L- or CD28-
for CD8 T cells) (CD45RA-CD62L) (BDPharmingen,
Franklin Lakes, NJ)-CD3-CD4(Caltag)-CD8(Caltag) and
CD28-CD3-CD8 (Caltag, Buckingham, UK)). The rela-
tive proportions of the naive and memory populations
in peripheral blood vary with age [25].
CMV serology
Serum from the blood sample taken at inclusion was
used for the enzyme immunoassay Eti-CytoK-G Plus
(Diasorin, Antony, France) to detect IgG antibodies to
CMV.
Immune Risk Phenotype criteria
To classify patients as IRP+ or IRP-, we defined the IRP
[16] as positive CMV serology plus at least one of the
following criteria: CD4/CD8 ratio < 1, CD8 T-cell count
> 600/μL (the reference value used in our laboratory for
routine testing), and CD28-CD8 T cell count above the
threshold determined by Fagnoni et al. [9] (300/μL) in
patients aged 80-99 years and > 210/μL in patients
younger than 80 years.
Statistical analysis
The prevalence of NI was computed using the total
number of included patients as the denominator, and
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the 95% confidence interval (95%CI) was estimated. We
compared the groups with and without NIs (NI+ and
NI-, respectively) regarding baseline characteristics, clin-
ical findings, and immunological findings. Since the
counts of CD4 and CD8 T cells may vary independently
from each other, the absolute counts are more reliable
than the relative percentages. Immunological findings
used in the comparison were the main lymphocyte sub-
set counts, naive or memory/effector status of CD4 and
CD8 T-cells, CMV serology, and IRP (as defined for our
study). Qualitative variables were described as number
(%) and compared using the Chi2-test or Fisher exact
test, as appropriate. Quantitative variables were
described as mean (± SD) or median (interquartile
range, IQR) as appropriate and compared using the
non-parametric Kruskal-Wallis test.
All tests were two-tailed and p values no greater than
0.05 were considered significant. No adjustments for
multiple comparisons were performed. Data were ana-
lysed using STATA software SE11 (Stata, College Sta-
tion, TX, USA).
List of abbreviations
CMV: cytomegalovirus; Ig G: Immunoglobulin G; IQR: interquartile range; IRP:
immune risk phenotype; NI: nosocomial infection; NK cell: natural killer cell.
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